Wednesday, December 16, 2020 As with most events in 2020 the 62nd American Society of Hematology Annual Meeting and Exposition was a virtual meeting held December 5-8. There were four presentations of note for trials that CCTG participated in: The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma Poster Presenter: Christopher Rushton Abstract: The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma (#1105) Authors: Christopher Rushton, Miguel Alcaide, Matthew Cheung, Neil R Michaud, Scott Daigle, Ryan N Rys, Sarah E Arthur, Marquisa Zrymiak, Jordan Davidson, Kevin R Bushell, Stephen Yu, Michael D. Jain, Lois E. Shepherd, Marco A. Marra, John Kuruvilla, Michael Crump, Koren Kathleen Mann, Sarit E Assouline, Joseph M. Connors, Christian Steidl, Nathalie A Johnson, David W. Scott and Ryan D Morin https://ash.confex.com/ash/2020/webprogram/Paper142871.html Alliance 10603 / CCTG ALC.2: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/ Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Oral Presenter: Frank G. Rücker Abstract: Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603) (#391) Authors: Frank G. Rücker, Ling Du, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph M Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Lynn Savoie, Jorge Sierra, Celine Pallaud, Miguel A. Sanz, Joop Jansen, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Richard A. Larson, Clara D. Bloomfield, Richard M. Stone, Hartmut Döhner, Christian Thiede and Konstanze Dohner https://ash.confex.com/ash/2020/webprogram/Paper139288.html Alliance A041202 / CCTG CLC.2E: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia Poster Presenter:Matthew C. Cheung Abstract: A Prospective Economic Analysis of Canadian Cancer Trials Group CLC.2E/ Alliance A041202 – A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia (#3428) Authors: Matthew C. Cheung, Nicole Mittmann, Carolyn Owen, Nizar Abdel-Samad, Graeme Fraser, Selay Lam, Michael Crump, Catherine Sperlich, Richard van der Jagt, Stephen Couban, Jennifer A. Woyach, Amy S. Ruppert, Allison M Booth, Sumithra J Mandrekar, Gail T. McDonald, Lois E. Shepherd, Anca Prica, Hope Yen, Bingshu E. Chen and Annette E. Hay https://ash.confex.com/ash/2020/webprogram/Paper136692.html SWOG S1826 / CCTG HDC.1: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Poster Presenter: Alex F. Herrera Abstract: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (#2969) Authors: Alex F. Herrera, MD, Hongli Li, Sharon M. Castellino, Sarah C. Rutherford, Kelly Davison, Andrew G Evans, Angela Punnett, Louis S. Constine, David C. Hodgson, Susan K Parsons, Anca Prica, Lale Kostakoglu, Margaret A. Shipp, Cara Laubach, Michael L. Leblanc, Michael Crump, Brad S. Kahl, John P. Leonard, Kara M. Kelly, Sonali M. Smith and Jonathan W. Friedberg https://ash.confex.com/ash/2020/webprogram/Paper136422.html
